Stage III NSCLC: low baseline MPV predicts poorer OS

  • Sakin A & al.
  • Sci Rep
  • 8 Mar 2019

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Lower pretreatment mean platelet volume (MPV) was an independent risk factor for poor survival in patients with inoperable stage III NSCLC who received concomitant chemoradiotherapy (CCRT).

Why this matters

  • Although other studies have shown an association between low MPV and OS, this is the first in patients with locally advanced NSCLC.
  • MPV is part of a routine blood panel and could be an easy way to identify the best candidates for CCRT.

Study design

  • 115 patients with inoperable stage III NSCLC received CCRT with cisplatin plus etoposide.
  • Funding: None disclosed.

Key results

  • 65 patients had low pretreatment MPV (≤9 fL), and 50 had higher levels (>9 fL).
  • Patients with MPV ≤9 fL had a significantly higher mean total platelet count (TPC; P=.005) and platelet distribution width (P=.027).
  • Overall, median OS was significantly longer in patients with MPV >9.0 fL vs those with MPV ≤9.0 fL (45 vs 19 months; P<.001>
  • OS was better with higher MPV regardless of stage or tumor histology.
  • After multivariable analysis, independent factors of OS were MPV (HR, 0.807; P=.034), Eastern Cooperative Oncology Group Performance Status score (HR, 4.428; P<.001 and total platelet count p=".041).</li">

Limitations

  • Single-center, retrospective study.